No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KA Kineta
- 0.690
- +0.004+0.57%
Trading Jul 22 11:37 ET
8.46MMarket Cap-492P/E (TTM)
0.727High0.680Low43.39KVolume0.699Open0.686Pre Close29.93KTurnover0.63%Turnover RatioLossP/E (Static)12.25MShares5.39052wk High-1.32P/B4.78MFloat Cap0.33452wk Low--Dividend TTM6.92MShs Float2888.200Historical High--Div YieldTTM6.85%Amplitude0.334Historical Low0.689Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Kineta Enters Into $5 Million Agreement With TuHURA Biosciences for Vista Blocking Immunotherapy; Shares Rise
Kineta (KA) said Monday it has entered into an exclusivity and right of first offer agreement with TuHURA Biosciences, granting the oncology company an exclusive right to buy its worldwide patents, patent rights, patent applications, product and development program assets and other rights and assets linked to its Vista blocking immunotherapy program, KVA12123, for a nonrefundable payment of $5 million.
Express News | Kineta Shares Are Trading Higher After the Company Announced That It Entered Into an Exclusivity and Right of First Offer Agreement With TuHURA Biosciences to Grant the Immune-oncology Company Exclusive Rights to Acquire Its Anti-VISTA Antibody
TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies
Express News | Kintara Therapeutics Inc - Under Terms of Agreement, Tuhura Will Pay Kineta $5.0 Mln
Express News | Kineta Inc: Kineta Will Receive a $5 Mln Nonrefundable Payment From Tuhura
Express News | Tuhura Biosciences Enters Into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s Kva12123 Novel Anti-Vista Checkpoint Inhibitor
Comments
$Kineta(KA.US$ broke resistance. Uptrending to 2.20. Borrow rate doubled and no shares available.
6
Kineta Announces Exclusivity and Right of First Offer Agreement for VISTA Blocking Antibody with TuHURA Biosciences.
Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company dedicated to the development of novel immunotherapies aimed at overcoming cancer immune resistance, has recently announced a massive milestone. The company has entered into an exclusivity and right of first offer agreement (the "Agreement"...
Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company dedicated to the development of novel immunotherapies aimed at overcoming cancer immune resistance, has recently announced a massive milestone. The company has entered into an exclusivity and right of first offer agreement (the "Agreement"...
1
$Kineta(KA.US$
Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
Kineta has entered an exclusivity and right of first offer agreement with TuHURA Biosciences for its KVA12123 immuno-oncology drug program. Under the agreement, TuHURA has the exclusive right to negotiate the acquisition of Kineta's assets, patents, and development program related to KVA12123. This right is valid until October 1, 2024, with possible extensio...
Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
Kineta has entered an exclusivity and right of first offer agreement with TuHURA Biosciences for its KVA12123 immuno-oncology drug program. Under the agreement, TuHURA has the exclusive right to negotiate the acquisition of Kineta's assets, patents, and development program related to KVA12123. This right is valid until October 1, 2024, with possible extensio...
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg